Subscribe to Newsletter
Subspecialties Cornea / Ocular Surface

The Burden of Dry Eye Disease

sponsored by Santen Pharmaceuticals

Dry eye disease (DED) is burdensome for both doctor and patient for three main reasons: high prevalence, many causes, and – especially in the case of severe DED – little in the way of effective treatment options. Up to 100 million people globally are thought to be affected by DED to some extent, and for many reasons, it has been both underdiagnosed and undertreated. Milder forms are rarely vision-threatening, and a lot of people with DED will go to their pharmacist, buy an over-the-counter lubricant, self-treat and make do. It can therefore take years before these people navigate through the path of pharmacist, general practitioner, optometrist, general ophthalmologist, until finally getting to see a cornea specialist. Furthermore, some patients show the signs, but not the symptoms of DED, further delaying their presentation to an ophthalmology clinic.

Nevertheless, a substantial volume of patients still present to ophthalmology clinics with DED. Indeed, it has been estimated that up to 60 percent of patients under the care of an ophthalmologist have some form of DED. Such patients are present in every subspecialty and in every clinic – even posterior segment specialists will talk of patients with fluctuating vision that leads to a DED diagnosis. Given that eye clinics are already busy enough dealing with aging baby-boomers with age-related ocular disorders, this is far from ideal.

It’s also far from ideal if you’re a patient with DED. Symptoms include red, tired, irritated, itchy eyes, gritty or burning sensations, light sensitivity, fluctuating vision. Everyday tasks like driving a car, working with a PC, or even being in a room with a fan heater can all be painful undertakings.

It’s not just the impact on quality of life that warrants concern; this is a disease that actively harms the eye

It’s not just the impact on quality of life that warrants concern; this is a disease that actively harms the eye, causing inflammatory damage to cells on the ocular surface. Then there’s the fact that it’s a disease with many causes: aging, air conditioning, air travel, autoimmune disease, androgen deficiency – these are just some that begin with the letter “A.” There really is no standard natural history of DED and there are many points where a patient can enter its vicious cycle (see Figure 1), and few places where patients can exit it – certain contributing factors (if present) like blepharitis or meibomianitis can be treated, which should help, but too often it isn't enough to exit the cycle. As DED can involve not just the cornea and conjunctiva, but also the lacrimal and meibomian glands too, there’s a complex interplay between the pathologies that develop in each site (Figure 1) that can all drive inflammatory pathways, accelerating ocular surface damage.

Figure 1. The many origins of dry eye disease (DED). Many systemic and external factors can result in dysfunction of one of the three main constituents of the lacrimal functional unit – the cornea, lacrimal glands, and meibomian glands. Impairment of any one of these then prolongs and drives the progression of DED by inflammatory, hyperosmolar and stress conditions that damage the other components of the ocular surface.

As we’ll explore in future issues of The Ophthalmologist, diagnosis is also a real challenge, but the big picture is that patients with DED are not happy. Gallup, the multinational management consulting company, conducted a poll in 2008 and found that:

  • 72 percent of patients were recommended artificial tears for their dry eye problem by physicians,
  • 82 percent of patients agreed that they wish there was something more effective to treat their dry eye, and
  • 97 percent of patients reported that their dry eye condition is frustrating.

An effective treatment would certainly improve this situation. The problem is that, for patients with severe DED, the treatments currently available – mostly artificial tears and lubricants – just aren’t that effective; they are essentially symptomatic treatments and do nothing to dampen inflammation or interfere with the disease processes. It’s therefore frustrating for not just the patient, but also the ophthalmologist, that nothing more – short of surgical or experimental interventions – can be done.

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Related Case Studies
The Missing Piece of the Dry Eye Puzzle

| Contributed by Quidel

Uncovering Ocular Comorbidity

| Contributed by Quidel

Finding Ocular Surface Inflammation

| Contributed by Quidel

Related Product Profiles
Subspecialties Cornea / Ocular Surface
Tear Osmolarity – Empowering. Established. Essential.

| Contributed by TearLab

Subspecialties Cornea / Ocular Surface
Preservative-Free Cyclosporine 0.1% Ophthalmic Emulsion

| Contributed by ImprimisRx

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine



The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: